Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThere is no licensed 90mg dose of tirzepatide in the UK. If you've searched for tirzepatide 90mg, you've likely encountered packaging or product descriptions that measure the total amount of hormone in a full pen cartridge — not a single weekly dose. Each Mounjaro KwikPen contains four weekly injections, so a 15mg-per-dose pen holds a total of 60mg across its four doses; no UK-licensed strength reaches 90mg per pen or per dose. Tirzepatide is a prescription-only medicine, and suitability for any dose is something a qualified prescriber assesses individually — not something chosen from a number on a label.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Picture this: you've been researching Mounjaro online, you've spotted a product described as tirzepatide 90mg, and now you're wondering whether you've missed a dose, whether someone is selling something stronger, or whether the UK simply doesn't stock it. It's a reasonable thing to wonder. The 90mg figure almost certainly comes from multiplying a per-dose strength by the number of injections in a pen or a multi-pen supply. Three 15mg pens, for example, contain 12 injections and 180mg of tirzepatide in total, but 90mg would represent three months' worth of a 7.5mg dose, or two months at 11.25mg, neither of which is a licensed UK strength. Sellers outside the regulated UK supply chain sometimes describe medicines using total-content figures rather than per-dose strengths, either through error or to obscure what is actually being sold.
The six UK-licensed strengths of tirzepatide are 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and 15mg per weekly injection. That is the complete list, as confirmed in the NHS tirzepatide medicines page. Any figure outside those six (including 90mg) does not correspond to a licensed product available through the regulated UK supply chain. If a listing uses unfamiliar dose numbers, that is a reason to pause, not proceed.
Tirzepatide treatment in the UK begins at 2.5mg per week. That starting point exists for a practical reason: it gives the body time to adjust to the medicine before the dose increases, reducing the intensity of nausea and other gastrointestinal effects that are most common in the early weeks. From there, the prescriber typically moves the dose up in 4-week steps (to 5mg, then 7.5mg, and so on) pausing at each level to check tolerability, and you can see exactly what that looks like in practice on our tirzepatide 30mg page, which walks through the early stages of the titration journey. The 15mg weekly injection is the highest licensed maintenance dose.
A question our prescribers hear most weeks is whether a higher dose would produce faster results. The honest answer is that the escalation schedule exists precisely because pushing the dose too quickly increases the risk of side effects without reliably improving outcomes. The titration pathway is a clinical design, not a commercial limitation, and our tirzepatide L page covers how that clinical design applies across the full licensed dose range. Anyone offering a flat 90mg product (whatever it actually contains) is not following that design, which should prompt serious questions about the source. You can read more about how the full Mounjaro treatment journey works on our Mounjaro overview page.
The MHRA has warned publicly about counterfeit and unlicensed weight-loss pens being sold online and through social media. Fake products have contained substances ranging from insulin to unknown compounds, the health risks are real and unpredictable. Unusual dose descriptions, prices significantly below the market rate, and sellers operating without a valid prescription process are all red flags flagged in the MHRA's Yellow Card reporting system, where you can also report a suspect product or seller directly.
The safe route to tirzepatide in the UK is a prescription issued following a clinical assessment by a GPhC-registered prescriber. If you want to understand how that process works and whether you'd be eligible, our tirzepatide information page covers the licensed eligibility criteria in detail. For context on treatment costs through a regulated UK service, our Mounjaro price comparison guide explains what a legitimate private prescription typically includes. And if you have questions about a specific dose level within the licensed range, our revision tirzepatide 90mg page addresses another commonly misunderstood total-pen-content figure in the same way this page does.
If you were searching because you're genuinely curious about starting treatment rather than a specific dose number, the weight-loss treatment overview is a good place to get a clear picture of what's available. Our clinical team is introduced on the clinical team page if you'd like to know who would be reviewing your case. Answers to common questions about the consultation process live on our FAQs page. When you're ready to find out whether treatment is right for you, check your eligibility with a free consultation, a real prescriber reads every submission.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.